International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 5, Issue 10 | Case Report | Open Access
Tessy López-Goerne*
Tessy López-Goerne 1,2* , Abel Santamaria1
1Department of Health Care, Autonomous Metropolitan University of Xochimilco, Mexico
2Department of Chemical and Biomolecular Engineering, Tulane University, USA
*Correspondence to: Tessy López-Goerne
Fulltext PDFThis research paper presents the clinical case of a 25-year-old male patient diagnosed with glioblastoma. This work is presented as a brief report because it is one of the first clinical cases in which a bionanocatalyst has been used for therapeutic purposes . Unlike studies published up to 2025, which focused on developing nanoparticles for the controlled release of chemotherapy (especially alkylating agents) or on combining temozolomide (TMZ) with other drugs, this work proposes a selective alternative that allows for the destruction of the tumor mass through the catalytic cleavage of DNA bonds without inducing toxicity.
The NPt bionanocatalyst is notable for its high biocompatibility (LD50 = 17 mg/ mL ). It consists of 1% platinum, the active metal, supported on titanium dioxide via a sol-gel synthesis that achieves complete dispersion of the platinum within the titanium dioxide, followed by functionalization. Thanks to the functionalized molecules on its surface, the catalyst targets only cancer cells, not healthy cells, as its mechanism of action involves the entry of the nanoparticle through receptor-mediated endocytosis. After the bionanocatalyst is released from the cell vacuole into the cytoplasm , some molecules target the mitochondria and attack mitochondrial DNA, while others target the nucleus to break the bonds of nuclear DNA.
GB ; Platinum nanoparticules ; titania, sol-gel ; LD50 ; MRI; SEM; MET
Tessy López-Goerne, Abel Santamaria. Glioblastoma treated with Pt/TiO 2 -1% Functionalized Bionanocatalyst. Int Clinc Med Case Rep Jour. 2026;5(10):1-11.